Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Somnomed.
RELATED STOCKHEAD STORIES
Director Trades
Directors Trades: This anti-snoring device maker needed capital to survive COVID-19; one director put in $3.7m
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Somnomed spins fairytale of a sleep cure in half-year results
Health & Biotech
Health: Oventus isn’t sleeping on the job because it’s making too much money
Health & Biotech
Dr Boreham’s Crucible: ResMed turbo-charges its sleep apnoea devices, races into new markets
Stockhead TV
VIDEO: The boom continues – 2019 tech sector wrap
Health & Biotech
My bank balance is bigger than yours: biotech quarterlies
Health & Biotech
Dr Boreham’s Crucible: How SomnoMed is placed in the $10.4 billion sleep apnoea market
Health & Biotech
Zoono is a $24m company. It just sold $33m worth of product
News
Quarterlies: Marley Spoon is spending now to profit later, aims to break even by 2020
Health & Biotech
A big Somnomed client just went out of business, but it’s not in Europe so it’s fine
Health & Biotech